Infinity Pharmaceuticals Inc (INFI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012291
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The company’s product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Partnerships 11
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
Licensing Agreements 16
PellePharm Enters into Licensing Agreement with Infinity Pharma 16
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 17
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 19
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 20
Equity Offering 22
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 22
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 23
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 25
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 26
Infinity Pharmaceuticals Inc – Key Competitors 28
Infinity Pharmaceuticals Inc – Key Employees 29
Infinity Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Strategy And Business Planning 31
Jan 11, 2016: Infinity Provides Key 2016 Goals and Financial Guidance 31
Financial Announcements 32
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 32
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 34
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 37
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 38
Nov 09, 2016: Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results 40
Aug 09, 2016: Infinity Provides Company Update And Reports Second Quarter 2016 Financial Results 42
May 04, 2016: Infinity Provides Company Update And Reports First Quarter 2016 Financial Results 44
Feb 23, 2016: Infinity Provides Company Update and Reports Full-Year 2015 Financial Results 46
Corporate Communications 48
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 48
Jan 04, 2017: Infinity Announces Organizational Changes 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
PellePharm Enters into Licensing Agreement with Infinity Pharma 16
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 17
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 19
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 20
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 22
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 23
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 25
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 26
Infinity Pharmaceuticals Inc, Key Competitors 28
Infinity Pharmaceuticals Inc, Key Employees 29
Infinity Pharmaceuticals Inc, Subsidiaries 30

★海外企業調査レポート[Infinity Pharmaceuticals Inc (INFI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Takeda Pharmaceuticals USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Takeda Pharmaceuticals USA Inc (TPUSA), formerly Takeda Pharmaceuticals North America Inc, a subsidiary of Takeda Pharmaceutical Company Ltd, is a developer, manufacturer and distributor of pharmaceutical drugs. The company’s products include pioglitazone and glimepiride, lubiprostone, piogl …
  • Schweitzer-Mauduit International Inc (SWM):企業の財務・戦略的SWOT分析
    Schweitzer-Mauduit International Inc (SWM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • AGL Energy Ltd:発電所・企業SWOT分析
    AGL Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Acuity Brands Inc (AYI):企業の財務・戦略的SWOT分析
    Acuity Brands Inc (AYI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Nostra Terra Oil and Gas Company plc (NTOG):企業の財務・戦略的SWOT分析
    Summary Nostra Terra Oil and Gas Company Plc (NTOG) is an oil and gas company. The company explores, produces, and develops oil and gas properties across the US. It holds interest in operating and non-operating working interests in its projects located in New Mexico, Permian Basin located in West Te …
  • Corcept Therapeutics Inc (CORT):製薬・医療:M&Aディール及び事業提携情報
    Summary Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic an …
  • AltheaDx Inc-医療機器分野:企業M&A・提携分析
    Summary AltheaDx Inc (AltheaDx) is a biotechnology company that offers molecular diagnostic services. The company provides tests such as cardiovascular tests, pain tests, thrombophilia tests and psychiatric tests. It provides diagnostic development, clinical trial and discovery services. AltheaDx’ s …
  • Reckitt Benckiser Group plc:企業のM&A・事業提携・投資動向
    Reckitt Benckiser Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Reckitt Benckiser Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • FGL Sports Ltd.:企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ameren Corporation (AEE)-エネルギー分野:企業M&A・提携分析
    Summary Ameren Corporation (Ameren) is a public utility holding company that generates, transmits and distributes electricity; and transmits and distributes natural gas through its subsidiaries. The company generates electricity through varied energy sources such as coal, nuclear, hydro, solar, natu …
  • Vector Group Ltd.:企業の戦略・SWOT・財務情報
    Vector Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Vector Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Vigor Shipyards, Inc:企業の戦略・SWOT・財務分析
    Vigor Shipyards, Inc - Strategy, SWOT and Corporate Finance Report Summary Vigor Shipyards, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pharmathen Global BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmathen Global BV (Pharmathen) is a pharmaceutical company with focus on the research and development of generics, active pharmaceutical ingredients (APIs), and finished formulations. Its vast product portfolio includes antibiotics, antimycotics, antivirals, antidiabetics and topical pain …
  • Pedernales Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Pedernales Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • The Dai-ichi Life Insurance Co Ltd:戦略・SWOT・企業財務分析
    The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Republic Services Inc (RSG):企業の財務・戦略的SWOT分析
    Republic Services Inc (RSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • RS Software (India) Limited (RSSOFTWARE):企業の財務・戦略的SWOT分析
    RS Software (India) Limited (RSSOFTWARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • DCP Midstream LP (DCP):企業の財務・戦略的SWOT分析
    DCP Midstream LP (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Kinder Morgan Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Kinder Morgan Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Kinder Morgan Inc (KMI) is a midstream energy infrastructure company that owns and operates through a network of pipelines and terminals. Its pipelines transport natural gas, crude oil, gasoline, conde …
  • Costco Wholesale UK Limited:企業の戦略・SWOT・財務分析
    Costco Wholesale UK Limited - Strategy, SWOT and Corporate Finance Report Summary Costco Wholesale UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆